BioCentury | Sep 21, 2018
Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million on Sept. 20 in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and...
BioCentury | Sep 20, 2018
Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and activator of transcription...
BioCentury | Apr 14, 2017
Company News

Immune-Onc, University of Texas deal

The centers granted Immune-Onc exclusive, global rights to develop and commercialize biotherapeutics that Immune-Onc says have applications in cancer immunotherapy and other diseases. Additionally, Immune-Onc entered into a multi-year research collaboration with both centers to...
BioCentury | Dec 15, 2016
Targets & Mechanisms

Keeping the Gas off AXL

With its development of an AXL decoy able to trap and sequester the native receptor’s ligand with femtomolar affinity, Aravive Biologics Inc. believes it has a biologic that can bypass the potency and selectivity issues...
BioCentury | May 30, 2016
Company News

Pelican, Cancer Prevention & Research Institute of Texas cancer news

CPRIT awarded Pelican a $15.3 million New Company Product Development Award to develop agonists directed at tumor necrosis factor (TNF) receptor superfamily member 25 ( TNFRSF25 ; DR3 ; LARD; TRAMP; WSL-1 ) to treat cancer. Pelican...
BioCentury | Apr 14, 2016
Strategy

Next stop: Houston

...Metaclipse moved from Atlanta to Texas to take advantage of the funding opportunities of the Cancer Prevention Research Institute of Texas...
...NASDAQ:AMGN), Thousand Oaks, Calif. Baylor College of Medicine, Houston, Texas Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Cancer Prevention Research Institute of Texas...
BioCentury | May 26, 2014
Company News

Aeglea, Mirna, Cancer Prevention & Research Institute of Texas (CPRIT) cancer news

CPRIT awarded three-year grants totaling up to about $45 million to cancer companies Mirna and Aeglea. Mirna will receive up to $25.1 million to develop compounds that mimic naturally occurring tumor suppressor microRNAs. The company's...
BioCentury | Mar 20, 2014
Translation in Brief

Translational tidbits

At least $440 million in new support for public-private partnerships was allocated last month globally. Almost $230 million of that amount is earmarked for the NIH 's Accelerating Medicines Partnership 1 ( see "Selected public-private partnerships...
BioCentury | Mar 3, 2014
Emerging Company Profile

CBS: Sniffing out cancer therapy

...focus: Cancer Clinical status: Preclinical Founded: 2013 by Csaba Szabo and Mark Hellmich University collaborators: Cancer Prevention Research Institute of Texas...
BioCentury | Dec 16, 2013
Company News

Cancer Prevention & Research Institute of Texas (CPRIT) cancer news

Former CPRIT Chief Commercialization Officer Jerald Cobbs was indicted by a grand jury in Travis County, Texas, related to his handling of an $11 million grant from CPRIT to Peloton Therapeutics Inc. (Dallas, Texas). The...
Items per page:
1 - 10 of 14
BioCentury | Sep 21, 2018
Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million on Sept. 20 in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and...
BioCentury | Sep 20, 2018
Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and activator of transcription...
BioCentury | Apr 14, 2017
Company News

Immune-Onc, University of Texas deal

The centers granted Immune-Onc exclusive, global rights to develop and commercialize biotherapeutics that Immune-Onc says have applications in cancer immunotherapy and other diseases. Additionally, Immune-Onc entered into a multi-year research collaboration with both centers to...
BioCentury | Dec 15, 2016
Targets & Mechanisms

Keeping the Gas off AXL

With its development of an AXL decoy able to trap and sequester the native receptor’s ligand with femtomolar affinity, Aravive Biologics Inc. believes it has a biologic that can bypass the potency and selectivity issues...
BioCentury | May 30, 2016
Company News

Pelican, Cancer Prevention & Research Institute of Texas cancer news

CPRIT awarded Pelican a $15.3 million New Company Product Development Award to develop agonists directed at tumor necrosis factor (TNF) receptor superfamily member 25 ( TNFRSF25 ; DR3 ; LARD; TRAMP; WSL-1 ) to treat cancer. Pelican...
BioCentury | Apr 14, 2016
Strategy

Next stop: Houston

...Metaclipse moved from Atlanta to Texas to take advantage of the funding opportunities of the Cancer Prevention Research Institute of Texas...
...NASDAQ:AMGN), Thousand Oaks, Calif. Baylor College of Medicine, Houston, Texas Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Cancer Prevention Research Institute of Texas...
BioCentury | May 26, 2014
Company News

Aeglea, Mirna, Cancer Prevention & Research Institute of Texas (CPRIT) cancer news

CPRIT awarded three-year grants totaling up to about $45 million to cancer companies Mirna and Aeglea. Mirna will receive up to $25.1 million to develop compounds that mimic naturally occurring tumor suppressor microRNAs. The company's...
BioCentury | Mar 20, 2014
Translation in Brief

Translational tidbits

At least $440 million in new support for public-private partnerships was allocated last month globally. Almost $230 million of that amount is earmarked for the NIH 's Accelerating Medicines Partnership 1 ( see "Selected public-private partnerships...
BioCentury | Mar 3, 2014
Emerging Company Profile

CBS: Sniffing out cancer therapy

...focus: Cancer Clinical status: Preclinical Founded: 2013 by Csaba Szabo and Mark Hellmich University collaborators: Cancer Prevention Research Institute of Texas...
BioCentury | Dec 16, 2013
Company News

Cancer Prevention & Research Institute of Texas (CPRIT) cancer news

Former CPRIT Chief Commercialization Officer Jerald Cobbs was indicted by a grand jury in Travis County, Texas, related to his handling of an $11 million grant from CPRIT to Peloton Therapeutics Inc. (Dallas, Texas). The...
Items per page:
1 - 10 of 14